Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0522213468
Sun, 26.06.2022
Achiko AG
Achiko AG Announces Annual Results for the Year Ended 31 December 2021
Zurich, 26 June 2022– Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces its financial results for the year ended 31 December 2021, and progress since then.
For the year ended 31 December 2021, the Group recorded a net loss of USD $9 [ … ]
Sun, 26.06.2022
Achiko AG
Achiko AG Announces Annual Results for the Year Ended 31 December 2021
Zurich, 26 June 2022– Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces its financial results for the year ended 31 December 2021, and progress since then.
For the year ended 31 December 2021, the Group recorded a net loss of USD $9 [ … ]
Mon, 20.06.2022
Achiko AG
Achiko AG – Publication of Annual Report and Annual Financial Statements 2021 to Occur by 26 June 2022
Zurich, 20 June 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that Achiko will publish its annual report and its annual financial statements for the [ … ]
Fri, 10.06.2022
Achiko AG
Achiko AG – Publication of Annual Report and Annual Financial Statements 2021 to Occur by 20 June 2022
Zurich, 10 June 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that Achiko will publish its annual report and its annual financial statements for the [ … ]
Mon, 06.06.2022
Achiko AG
Achiko AG – Publication of Annual Report and Annual Financial Statements 2021 to Occur by 10 June 2022
Zurich, 6 June 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that Achiko will publish its annual report and its annual financial statements for the ye [ … ]
Tue, 31.05.2022
Achiko AG
Achiko AG – Publication of Annual Report and Annual Financial Statements 2021 to Occur by 6 June 2022
Zurich, 31 May 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that Achiko will publish its annual report and its annual financial statements for the yea [ … ]
Wed, 25.05.2022
Achiko AG
Achiko AG Secures CHF 1.25 million Financing with Strategic Investors Buranto AG and Negma Group
- Buranto AG provided a CHF 250,000 loan facility and existing strategic investor Negma Group provided a CHF 1.0 million loan facility
- Derek Brandt, co-owner of Buranto AG, joins Achiko’s Advisory Board
- Funds to be used for production in Indones [ … ]
Thu, 19.05.2022
Achiko AG
Achiko AG Reports Key Unaudited Financial Results for the Year Ended 31 December 2021
- Full year unaudited adjusted EBITDA loss [corrected] of USD$5,272,179 (2020: USD$8,728,709 loss) following 6 months unaudited loss of USD$3,915,136 to 30 June 2021 and closing Shareholders Equity of USD($4,297,969) (2020: USD$4,052,073).
- Restructuring of th [ … ]
Thu, 19.05.2022
Achiko AG
Achiko AG Reports Key Unaudited Financial Results for the Year Ended 31 December 2021
- Full year unaudited adjusted EBITDA of USD$5,272,179 (2020: USD$8,728,709) following 6 months unaudited of USD$3,915,136 to 30 June 2021 and closing Shareholders Equity of USD$4,297,969 (2020: $4,052,073).
- Restructuring of the European operations in mid-202 [ … ]
Tue, 17.05.2022
Achiko AG
Achiko AG Obtains CE Mark for AptameXTM Covid-19 Rapid Test
- Registered AptameX and has obtained a CE Mark, allowing the product to be sold in 27 countries in the EU
- AptameX has unique performance advantages over other rapid tests through its use of DNA aptamers
- The Company expects to have AptameX in widespread commercial availability in Q [ … ]